Clinical Implementation and Future Practice Considerations

Dr. Vachhani asks about remaining gaps in PV management and key monitoring points for community oncology practitioners. Dr. El Chaer emphasizes keeping ELN resistance and intolerance criteria as practical, structured checklists for every patient follow-up visit. When these criteria are not met, clinicians should raise alarms about whether patient disease is progressing to myelofibrosis or remains PV with suboptimal control.

Recommended monitoring frameworks include complete blood count with differential every three months, symptom assessment using MPN10 or simple structured verbal screening at every visit, and spleen assessment by palpation or imaging (annual imaging for myelofibrosis patients, repeat imaging for PV when spleen size changes are suspected). Phlebotomy frequency serves as surrogate marker for cytoreductive adequacy - requiring more than 3-4 phlebotomies annually indicates uncontrolled disease.

White blood cell count focus has become critically important as a major thrombotic risk factor in these patient populations. Pattern recognition, especially uptrending patterns rather than isolated data points, becomes essential. Two white blood cell count data points above 11,000 warrant reconsidering standard therapy management despite hematocrit control. Available newer drug options provide treatment alternatives while recognizing that hematocrit below 45% is insufficient by itself anymore.

Low thresholds for referral to MPN specialists or centers of excellence are recommended, as these centers typically have clinical trial access and can help with challenging cases. Annual check-ins with MPN specialists are suggested when specialty centers are not readily available, ensuring nothing gets missed or overlooked and providing access to newer available therapies. This becomes particularly important given evolving evidence and guidelines from ongoing conferences and updated recommendations.

Dr. Vachhani concludes by emphasizing key management principles: managing beyond hematocrit alone to include white blood cell count and platelet attention, addressing patient symptom burden, and utilizing disease-modifying therapies earlier rather than later. These comprehensive approaches represent significant advances in PV management, moving beyond traditional single-parameter control toward holistic disease management strategies that address multiple disease aspects simultaneously while personalizing treatment approaches for individual patient needs and circumstances.